Catalog No.
YFH02201
Expression system
E. coli
Species
Felis catus (Cat) (Felis silvestris catus)
Protein length
Leu25-Leu169
Predicted molecular weight
18.55 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
NP_001138982.1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
programmed cell death protein 1 precursor, PDCD1
Immune checkpoint molecules performance in ANCA vasculitis., PMID:39537557
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition., PMID:38670972
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade., PMID:34239137
NASH limits anti-tumour surveillance in immunotherapy-treated HCC., PMID:33762733
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic., PMID:32682248
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia., PMID:32513686
Immune-related adverse events of checkpoint inhibitors., PMID:32382051
Successful management of refractory immune-mediated enterocolitis with cyclosporine., PMID:32278241
[An integral view of cancer (III). Evaluation of new biomarkers and treatment strategies]., PMID:32199599
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma., PMID:32173382
Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern., PMID:31838162
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types., PMID:30165419
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma., PMID:28487385
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition., PMID:28302866
PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis., PMID:20087161
For research use only. Not for human or drug use.
